One in eight American adults is now taking a GLP-1 drug. Let that number settle. A KFF Health Tracking Poll from November 2025 found that 12% of U.S. adults report currently using medications like Ozempic, Wegovy, or Mounjaro for weight loss or chronic conditions. Nearly one in five say they have tried them at some point. The oral version of Wegovy just got FDA approval in December. Eli Lilly's competing pill is close behind. The market is accelerating.
So the question everyone is asking, "Should I try a GLP-1 for weight loss?" is legitimate. Here is what the research actually says. Not the influencer testimonial. Not your coworker's before-and-after photos. The controlled, peer-reviewed, published data.
The Efficacy Is Real. Genuinely Real.
I want to be clear about this because I refuse to be the scientist who dismisses good data out of contrarianism. GLP-1 receptor agonists work for weight loss, and the evidence is strong. The STEP clinical trials showed semaglutide producing approximately 15% mean body weight loss over 68 weeks. That is a 33-pound loss for someone starting at 220. For a non-surgical intervention, that is remarkable.
The cardiovascular benefits are also well-documented. Analyses show reduced risk of major cardiovascular events while patients are actively taking these medications. The OASIS 4 trial confirmed that even the new oral semaglutide produced 13.6% mean weight loss at 64 weeks. These are not marginal effect sizes. These are clinically meaningful outcomes that can transform metabolic health.
I am not here to tell you GLP-1s do not work. They do. That is settled science. I am here to tell you about the three problems almost nobody discussing these drugs wants to confront honestly.
Problem One: The Regain Cliff
A systematic review and meta-analysis published in the BMJ in January 2026 analyzed 37 studies involving over 9,300 adults. University of Oxford researchers found that after stopping GLP-1 medications, weight regain averaged 0.8 kg (about 1.8 pounds) per month for newer drugs like semaglutide and tirzepatide. Their projection: return to baseline weight within approximately 18 months of stopping.
This is not a surprise to anyone paying attention. The STEP 1 trial extension, published in Diabetes, Obesity and Metabolism, followed 327 participants after treatment withdrawal. Mean weight loss on semaglutide was 17.3% at week 68. One year after stopping, participants had regained two-thirds of that lost weight. Net loss at week 120: just 5.6%.
The Oxford meta-analysis found something else worth noting: weight regain after stopping drugs was faster than after ending behavioral weight loss programs by approximately 0.3 kg per month. The researchers offered a plausible explanation. People using drugs do not need to consciously change eating habits to lose weight. When the drug stops, they have not developed the practical strategies to maintain the loss.
This brings me to the number that should alarm everyone involved in prescribing these medications.
Problem Two: Almost Nobody Stays On
A real-world analysis of 4,066 commercially insured adults published in the Journal of Managed Care & Specialty Pharmacy found that GLP-1 persistence was just 32.3% at one year. Only 27.2% were adherent, meaning they were taking the medication as prescribed. A population-based study of 77,310 Danish semaglutide users, presented at the 2025 European Association for the Study of Diabetes, confirmed the pattern: more than half stopped within a year.
Prime Therapeutics' three-year data is worse. Persistence dropped to 15% at two years. Only 14% of patients remained on Wegovy after three years. Think about that arithmetic. The drug works while you take it. Two-thirds of people stop within a year. Those who stop regain two-thirds of the weight within another year. The population-level impact shrinks fast.
Cost is a major driver. The KFF poll found 56% of GLP-1 users said the drugs were difficult to afford. Fourteen percent said they stopped specifically because of cost. Side effects matter too: about half of users report nausea, a third report diarrhea. And Medicare still does not cover these drugs for weight loss in 2026.
Problem Three: The Muscle Question Is Not Settled
This is where I get genuinely frustrated with the discourse. Studies report that anywhere from 25% to 40% of weight lost on GLP-1 medications is lean mass, not fat. The STEP 1 and SUSTAIN 8 trials found 39 to 40% of weight lost was lean mass. A Lancet Diabetes & Endocrinology paper noted that the annual rate of muscle loss on GLP-1s is several times greater than age-related decline.
Some researchers, including those publishing in JAMA, argue this loss is "adaptive" and proportional to the weight lost. Fair point. Any weight loss method produces some lean mass reduction. But here is what concerns me: an NPR report from this month highlighted that people using GLP-1s tend to lose muscle first, then regain fat when they stop. That asymmetry, losing muscle on the way down and gaining fat on the way back up, creates a body composition trajectory that could be genuinely harmful over repeated cycles.
Mass General Brigham researchers have stated clearly that combining high protein diet and consistent exercise with GLP-1 treatment offers the greatest benefit in preserving muscle. That is the right recommendation. But how many prescriptions come with a structured resistance training and nutrition protocol? Almost none.
A retrospective study found that over 22% of patients developed nutritional deficiencies within 12 months of starting GLP-1 therapy. Vitamin D deficiency alone hit 13.6%. When you are suppressing appetite this aggressively, you had better be deliberate about what goes into the reduced calories you are eating.
My Actual Recommendation
If you have clinical obesity or serious metabolic disease, GLP-1 medications are a legitimate, evidence-based treatment option. The data supports their use under medical supervision. Full stop.
But you need to enter this with eyes open. This is likely a lifelong commitment. If you cannot afford the medication indefinitely, if you are not going to pair it with resistance training at least twice weekly, if you are not going to consume adequate protein (at minimum 0.5 to 0.9 grams per pound of body weight daily), you are setting yourself up for a cycle of loss and regain that may leave you metabolically worse than where you started.
GLP-1 medications are not a shortcut. They are a tool. And like any tool, they are only as good as the system you build around them. The fundamentals still matter: progressive overload, adequate protein, sufficient sleep, stress management. A GLP-1 without those fundamentals is a temporary fix masquerading as a solution.
Show me the study that demonstrates long-term outcomes for GLP-1 patients who also lift weights and eat adequate protein. That is the trial I want to see. Until then, I will keep recommending the boring stuff. Because the boring stuff works. It just does not make pharmaceutical companies $50 billion a year.
